MEI Pharma Inc (MEIP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MEI Pharma Inc (MEIP) has a cash flow conversion efficiency ratio of -0.145x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.46 Million) by net assets ($16.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MEIP net asset quality index to measure how much of total assets are equity-financed.
MEI Pharma Inc - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how MEI Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of MEI Pharma Inc to evaluate the quality of earnings relative to operating cash generation.
MEI Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MEI Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Haitai Confectionery and Foods Co Ltd
KO:101530
|
0.042x |
|
CLERHP Estructuras S.A
MC:CLR
|
-0.061x |
|
Uni Charm Indonesia PT
JK:UCID
|
0.014x |
|
Kura Sushi Asia Co Ltd
TWO:2754
|
0.118x |
|
Taegu Broadcasting Corporation
KQ:033830
|
-0.041x |
|
MLRN Projects and Trade Ltd
TA:MLRN
|
-0.419x |
|
Westag & Getalit ST O.N.
F:WUG
|
0.015x |
|
Spanish Mountain Gold Ltd
V:SPA
|
0.001x |
Annual Cash Flow Conversion Efficiency for MEI Pharma Inc (2003–2025)
The table below shows the annual cash flow conversion efficiency of MEI Pharma Inc from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see how much is MEI Pharma Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $16.93 Million | $-20.84 Million | -1.231x | +19.46% |
| 2024-06-30 | $33.02 Million | $-50.47 Million | -1.529x | +28.28% |
| 2023-06-30 | $24.62 Million | $-52.48 Million | -2.131x | -129.18% |
| 2022-06-30 | $52.41 Million | $-48.75 Million | -0.930x | -20.35% |
| 2021-06-30 | $41.36 Million | $-31.96 Million | -0.773x | -276.44% |
| 2020-06-30 | $78.22 Million | $34.26 Million | 0.438x | +171.35% |
| 2019-06-30 | $47.93 Million | $-29.42 Million | -0.614x | -45.41% |
| 2018-06-30 | $50.46 Million | $-21.30 Million | -0.422x | -715.66% |
| 2017-06-30 | $50.84 Million | $3.49 Million | 0.069x | +115.99% |
| 2016-06-30 | $41.65 Million | $-17.86 Million | -0.429x | +8.68% |
| 2015-06-30 | $59.79 Million | $-28.07 Million | -0.469x | -9.07% |
| 2014-06-30 | $45.19 Million | $-19.45 Million | -0.430x | -49.43% |
| 2013-06-30 | $34.87 Million | $-10.04 Million | -0.288x | +81.29% |
| 2012-06-30 | $4.60 Million | $-7.08 Million | -1.540x | +57.51% |
| 2011-06-30 | $1.79 Million | $-6.50 Million | -3.624x | -166.59% |
| 2010-06-30 | $7.38 Million | $-10.03 Million | -1.359x | -95.94% |
| 2009-06-30 | $15.21 Million | $-10.55 Million | -0.694x | +0.23% |
| 2008-06-30 | $16.54 Million | $-11.50 Million | -0.695x | +11.18% |
| 2007-06-30 | $13.78 Million | $-10.79 Million | -0.783x | +21.31% |
| 2006-06-30 | $9.13 Million | $-9.09 Million | -0.995x | -194.53% |
| 2005-06-30 | $16.52 Million | $-5.58 Million | -0.338x | +2.78% |
| 2004-06-30 | $22.94 Million | $-7.97 Million | -0.347x | -11.98% |
| 2003-06-30 | $5.93 Million | $-1.84 Million | -0.310x | -- |
About MEI Pharma Inc
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, … Read more